Proactive Investors - Run By Investors For Investors

Novogen signs agreement to facilitate brain cancer clinical trials in China

Novogen is developing a novel targeted therapy to treat glioblastoma multiforme (GBM).
a human brain
GBM is the most aggressive form of brain cancer

Novogen Limited (ASX:NRT) has entered into an agreement with Cedrus Investments Ltd for advisory services to establish a corporate structure focused on the Greater China region.

Novogen is an emerging oncology-focused biotechnology company, based in Sydney.

The new corporate entity will enable Novogen to interact directly with the Chinese Food and Drug Administration (CFDA) for future clinical trials in China.

The agreement defines the key terms, with most of the work expected to be conducted in the first half of calendar 2018.

It is also expected that the Chinese entity will be a Wholly Foreign Owned Enterprise (WFOE), headquartered in Shanghai.

Novogen is developing GDC-0084, a novel targeted therapy that modulates the PI3K pathway to treat glioblastoma multiforme (GBM).

GBM is the most common and most aggressive form of brain cancer.

Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials this year.

Novogen has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.

The partnership with Cedrus Investments will help Novogen to engage with researchers and investors to support the development of its current and future pipeline.

View full NRT profile View Profile

Novogen Ltd Timeline

August 05 2015

Related Articles

August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use